Findings

What do systematic reviews say?

4,756 questions · 11,779 findings · 747 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,205 · 27.2%GRADE not reported 628 · 5.3%Very low 3,261 · 27.7%Low 2,913 · 24.7%Moderate 1,453 · 12.3%High 319 · 2.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Alarm plus other intervention vs other interventions

Proportion of children with adverse events · children with nocturnal enuresis

1 finding from 1 review

Alarm interventions for nocturnal enuresis in children 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
GRADE not reported

Alarm vs placebo drug

Proportion of children achieving 14 consecutive dry nights by the end of treatment · children with nocturnal enuresis

Alarm may leads to higher proportion of children achieving 14 consecutive dry nights by the… compared with placebo drug (low certainty).

1 finding from 1 review

Alarm interventions for nocturnal enuresis in children 2020 · Cochrane Headline outcomes only
RR 1.59 [1.16, 2.17]
2 studies · 181 participants
Low

Alarm vs placebo drug

Proportion of children dry at · children with nocturnal enuresis

The review found no eligible studies for this question.

1 finding from 1 review

Alarm interventions for nocturnal enuresis in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alarm vs placebo drug

Proportion of children with adverse events · children with nocturnal enuresis

1 finding from 1 review

Alarm interventions for nocturnal enuresis in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2 participants
GRADE not reported

Intervention not reported

Death at one year · adults with renal vasculitis

The intervention showed no clear difference in death at one year (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.04 [0.57, 1.92]
5 studies · 267 participants
Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Dialysis · adults with renal vasculitis

Pulse cyclophosphamide showed no clear difference in dialysis at end of study compared with continuous cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.9 [0.92, 3.91]
4 studies · 245 participants
Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Remission · adults with renal vasculitis

Pulse cyclophosphamide showed no clear difference in remission at 6 months compared with continuous cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.03 [0.93, 1.13]
2 studies · 176 participants
Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · adults with renal vasculitis

Pulse cyclophosphamide may leads to higher relapse at the end of compared with continuous cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.79 [1.11, 2.87]
4 studies · 235 participants
Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Adverse events ‐ treatment failure · adults with renal vasculitis

Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.36 [0.115, 12.56]
2 studies · 82 participants
Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Serious infections · adults with renal vasculitis

Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.71 [0.38, 1.33]
4 studies · 278 participants
Low

Rituximab vs cyclophosphamide

Death at 6 months · adults with renal vasculitis

Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1 [0.21, 4.7]
2 studies · 241 participants
Moderate

Rituximab vs cyclophosphamide

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs cyclophosphamide

Dialysis · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs cyclophosphamide

Remission · adults with renal vasculitis

Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.02 [0.79, 1.32]
2 studies · 236 participants
Moderate

Rituximab vs cyclophosphamide

Relapse · adults with renal vasculitis

Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.43 [0.18, 11.31]
1 study · 38 participants
Low

Intervention not reported

Serum creatinine at 1 year · adults with renal vasculitis

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 156 participants
Low

Rituximab vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.11 [0.72, 1.71]
2 studies · 241 participants
Moderate

Rituximab vs cyclophosphamide

Serious infections · adults with renal vasculitis

Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.89 [0.62, 1.92]
2 studies · 241 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Death at 6 months · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25 [0.35, 4.46]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found